Related Experiment Video
Updated: May 15, 2026
07:34
Quantitative Determination of De Novo Fatty Acid Synthesis in Brown Adipose Tissue Using Deuterium Oxide
Published on: May 12, 2023
SREBP: a novel therapeutic target.
1Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shangha, China. xiaxu@sibcb.ac.cn
Acta Biochimica Et Biophysica Sinica
|December 22, 2012
Summary
Sterol regulatory element-binding proteins (SREBPs) are key regulators of lipid metabolism. Inhibiting SREBPs offers a promising therapeutic strategy for metabolic diseases like diabetes and fatty liver.
Area of Science:
- Biochemistry
- Molecular Biology
- Metabolic Research
Background:
- Sterol regulatory element-binding proteins (SREBPs) are crucial transcription factors.
- SREBPs regulate genes involved in cholesterol, fatty acid, and triglyceride biosynthesis.
- Dysregulation of SREBPs is linked to metabolic disorders.
Purpose of the Study:
- To review SREBP processing and regulatory mechanisms.
- To explore the role of SREBPs in lipid metabolism and related diseases.
- To discuss recent functional studies and therapeutic potential.
Main Methods:
- Literature review of SREBP processing.
- Analysis of regulatory pathways (insulin, cAMP, vitamin A).
- Examination of miRNA interactions in lipid metabolism.
Main Results:
- SREBP processing is a complex, multi-step pathway.
- Insulin, cAMP, and vitamin A significantly modulate SREBP activity.
- miRNAs play a role in regulating lipid metabolism via SREBPs.
- Recent studies highlight SREBP's involvement in metabolic diseases.
Conclusions:
- SREBP pathway is central to lipid homeostasis.
- Targeting SREBPs presents a novel therapeutic avenue.
- Inhibition of SREBP may treat type II diabetes, insulin resistance, fatty liver, and atherosclerosis.
Related Concept Videos
01:27Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:45Regulation of Nuclear Protein Sorting
Nuclear protein sorting regulates nucleus composition and gene expression, crucial for determining the fate of a eukaryotic cell. Hence, the entry and exit of molecules across the nuclear envelope is a tightly controlled process. Nuclear protein sorting can be inhibited by one of the following ways: 1) masking cargo signal sequences, 2) modifying the nuclear receptor's affinity for cargo, 3) controlling the nuclear pore size, 4) retaining the cargo during its transit to the cytosol or the...
01:31Transducer Mechanism: Nuclear Receptors
Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:31Regulation of the Unfolded Protein Response
Inositol-requiring kinase one or IRE1 is the most conserved eukaryotic unfolded protein response (UPR) receptor. It is a type I transmembrane protein kinase receptor with a distinctive site-specific RNase activity. As the binding mechanics of the misfolded proteins with the N-terminal domain of IRE-1 are unclear, three binding models — direct, indirect, and allosteric -- are proposed for receptor activation. Nevertheless, it is known that once a misfolded protein associates with IRE1, it...